The 47th Annual Ishmael Rheumatology Symposium and Inaugural Morris Reichlin Memorial Lectureship, 22003


The 47th Annual Ishmael Rheumatology Symposium and Inaugural Morris Reichlin Memorial Lectureship, 22003 Banner

Add to Calendar The 47th Annual Ishmael Rheumatology Symposium and Inaugural Morris Reichlin Memorial Lectureship, 22003 10/1/2021 7:30:00 AM 10/1/2021 5:00:00 PM America/Chicago For More Details: https://ouhsc.cloud-cme.com/course/courseoverview?EID=11309 Description: This intensive one day offering that includes a review and update on major subject areas in rheumatology. The faculty chosen to speak are recruited locally and from nationally recognized leaders in their fields. The topics are chosen from the prior years participant suggestions. The seminars are focused on practical diagnosis, treatment, and latest research in areas related to the successful delivery o... Zoom Videoconference false MM/DD/YYYY


Date & Location
Friday, October 1, 2021, 7:30 AM - 5:00 PM CST, Zoom Videoconference

Target Audience
Specialties - Allergy/Immunology, Family Medicine, General Medicine, Hematology, Immunology, Internal Medicine, Orthopaedics, Pulmonary Medicine, Research, Rheumatology
Professions - Advanced Practice Registered Nurse (APRN), Industry Professional, Licensed Practical Nurse (LPN), Medical Student, Non-Physician, Nurse Practitioner (NP), Physician, Physician Assistant (PA), Resident

Overview

This intensive one day offering that includes a review and update on major subject areas in rheumatology. The faculty chosen to speak are recruited locally and from nationally recognized leaders in their fields.  The topics are chosen from the prior years participant suggestions.  The seminars are focused on practical diagnosis, treatment, and latest research in areas related to the successful delivery of rheumatology health care and patient outcomes. The University of Oklahoma College of Medicine faculty is nationally recognized for their expertise in the management of complex conditions that is unavailable elsewhere in the state, region or sometimes even the nation. This is a very fast-paced symposium with five lectures and concurrent “meet the professor” sessions, conducted in a small-group discussion format. Each session will include time for questions and answers. The course combines best practice strategies and education through case studies and lectures.

Overall Professional Practice Gaps:
Gap 1: Pregnancy in rheumatic conditions can lead to poor maternal and fetal outcomes. Health care providers may not be aware that evidence-based guidelines to manage pregnancy in rheumatology conditions have been recently published entitled: 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.
Gap 2: Lupus nephritis is difficult to treat but guidelines are available as well as new treatments. Physicians may be unaware that in 2019, the joint guidelines for the management of adult and pediatric lupus nephritis were updated by the European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA). 
Gap 3: Practitioners vary widely in their screening, surveillance, and treatment of lupus nephritis (LN).
Gap 4: Practitioners may desire additional information about the two recently FDA approved treatments for lupus nephritis and other therapies in the pipeline.4
Gap 5: Diagnosis and treatment of the inflammatory myopathies continues to be a challenge. Presentation may be heterogeneous and extra-muscular features may dominate the clinical picture. Practitioners may not be aware of the current knowledge of the clinical associations and the possible pathogenetic implications of the myositis autoantibodies, which is needed for optimal clinical use of these autoantibodies.
Gap 6: Practitioners may not be aware of the different methods used to test for myositis autoantibodies, which could affect results and clinical implications. Understanding the differences can help in interpretation of autoantibody tests.
Gap 7: Physicians may be unaware of the multitude of rheumatic complications occurring after COVID-19, including long COVID, and vaccine responses on rheumatic medications, and outcomes of rheumatic patients that get COVID-19. 
 Gap 8: A positive antinuclear antibodies (ANA) can be found in up to 25% of women in the United States and a positive ANA remains as one of the most common reasons for referral to a rheumatologist. Gaps exist in: Identifying the features of ANA positivity which are associated with development of a systemic autoimmune rheumatic disease.|
Gap 9:  Identification of environmental factors that contribute to autoantibody positivity in individuals who do not yet have a systemic autoimmune rheumatic disease. 
Gap 10: Evaluation of high-risk factors for disease transition to classified autoimmune rheumatic disease in individuals with undifferentiated connective tissue disease.


Objectives
Upon completion of this activity, participants will improve their competence and performance by being able to:

  1. Describe how pregnancy outcomes in lupus data was assessed and interpreted.
  2. Demonstrate how to implement pregnancy guidelines in the clinical care of patients.
  3. Estimate risks of medication use during lupus pregnancies with risks of under treated disease.
  4. Summarize the temporal changes in pregnancy outcomes in SLE as management paradigms have evolved.
  5. Describe lupus nephritis screening and surveillance guidelines.
  6. Identify lupus nephritis treatment guidelines.
  7. Examine two FDA approved therapies for lupus nephritis: Belimumab (Benlysta), Voclosporin (Lupkynis).
  8. Discuss potential future lupus nephritis therapies.
  9. Describe the clinical associations of myositis autoantibodies.
  10. Recognize the characteristics, advantages and disadvantages of different testing methods for myositis autoantibodies.
  11. Use myositis autoantibodies in the diagnosis and classification of patients who may have myositis.
  12. Evaluate whether people receiving immunosuppressive drugs are more susceptible to initial infection with SARS-CoV-2.
  13. Predict the outcomes of COVID-19 in immunosuppressed individuals.
  14. Discuss clinical management in patients with autoimmune diseases, including COVID-19 vaccine efficacy and treatment and prevention of SARS-COV-2 infections.
  15. Identify autospecificities that can assist with identifying individuals with low risk of serious autoimmune rheumatic disease
  16. Utilize currently available testing to evaluate environmental risk factors for transition to SLE and other autoimmune rheumatic diseases in autoantibody positive individuals (with or without UCTD)
  17. Discuss autoantibodies which are commonly found in post-acute sequelae of COVID19, along with associated rheumatic disease symptoms
  18. Describe the earliest clinical and serologic features of systemic lupus erythematosus (SLE)

Registration

Regular Registration (9/28/2021):

Virtual Registration Fees:
Physician (MD, DO) Virtual, Regular Rate - $125.00
Other Healthcare Providers ( PA, Nurses, PharmD, etc.) Virtual, Regular Rate - $125.00

OUHSC Fellows, Virtual, Regular Rate - $125.00 ***
OUHSC Residents, Medical Students, Virtual, Regular Rate - $125.00 *** 
OUHSC Rheumatology Faculty, Virtual, Regular Rate - $125.00 ***
VA Rheumatology PAs, Virtual, Regular Rate - $125.00 ***

*** Please contact Nicole L. Lung for promo code before registering. (405-271-2330 / [email protected])



Registration Notes:
• Registration Fee for Virtual attendance includes course materials and CME credit.

• No registration refunds will be made after September 20, 2021.
• Written notification of cancellation must be postmarked before September 20, 2021.
• Cancellation fee is $25.
• Confirmations will be emailed. (This annual conference is subject to cancellation if registration is insufficient, in which case all registration fees will be refunded.)



Accreditation

The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC Accreditation Statement: 
OU Medicine, Inc. is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

CNE Disclosure Statements: 
OU Medicine, Inc. is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

6.00 CNE contact hours will be awarded for meeting the following criteria: 90% attendance of conference, completion and submission of evaluation form.

This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest.

 

ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 5.00 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Within 60 days of the end of the session, ABIM MOC Points will be reported on your behalf.

For information about ACCME accreditation and ABIM MOC for this session, please email myrna [email protected].

By providing your ABIM number, you consent to have the OUHSC CPD Office submit your participation in this activity to the ABIM through the ACCME PARS system.

Learning Format: Live Virtual Activity


AAFP Accreditation Statement: 
The AAFP has reviewed The 47th Annual Ishmael Rheumatology Symposium and Inaugural Morris Reichlin Memorial Lectureship and deemed it acceptable for up to 6.00 In-Person, Live (could include online) AAFP Elective credit. Term of Approval is from 10/01/2021 to 10/01/2021. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



AAPA Accreditation Statement:
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 6 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 10/1/2021 to 10/1/2021. AAPA reference number: CME-203447.





Additional Information

Nondiscrimination Statement:
The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides. Inquiries regarding non-discrimination policies may be directed to: Shaniqua Crawford, JD, Institutional Equity Officer and Title IX Coordinator, 405-325-3546, [email protected], or visit www.ou.edu/eoo.html. 

Accommodation Statement:
Accommodations on the basis of disability are available Nicole L. Lung at (405) 408-3198 or [email protected] by contacting as soon as possible.

Acknowledgement of Commercial and In-Kind Support:
Commercial support is financial, or in-kind, contributions given by a ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is one whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. 

Appropriate acknowledgement of all commercial and in-kind support will be given at the time of the educational activity.

Disclaimer Statement:
Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Faculty and Presenters Disclosure: 
It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also disclose discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s). 

 


Credits
AMA PRA Category 1 Credits™ (6.00 hours), AAPA Category 1 CME Credit (6.00 hours), ABIM MOC Part 2 (5.00 hours), American Academy of Family Phy Elective Credits (6.00 hours), ANCC Nursing Contact Hours (6.00 hours), Non-Physician Attendance (6.00 hours)